Search clinical trials for: Camrelizumab Nab-Paclitaxel S-1

Total 1817 results

Zhongshan Hospital Xiamen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Stage IV Gastric Cancer With Metastasis
Hebei Medical University

Not yet recruiting

Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer
Chinese PLA General Hospital

Recruiting

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | PDAC - Pancreatic Ductal Adenocarcinoma

China
Peking Union Medical College Hospital

Recruiting

The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.

Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC

China
Chang Gung Memorial Hospital

Recruiting

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma (GAS)

Metastatic Pancreatic Adenocarcinoma

Taiwan
Yang Jianjun, PhD

Recruiting

Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer

Advanced Gastric Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
Zhejiang Cancer Hospital

Recruiting

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Cancer

China
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
Fudan University

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer

China
AIPING ZHOU

Completed

The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma

Biliary Tract Cancer

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Head and Neck Squamous Cell Carcinoma

China
Changhai Hospital

Recruiting

Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)

Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer

Pancreatic Neoplasms

China
Peking Union Medical College Hospital

Unknown

Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Peking Union Medical College Hospital

Unknown

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Shanghai Zhongshan Hospital

Not yet recruiting

Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer

Gastric Cancer
Hutchmed

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Gastric Cancer | Gastroesophageal-junction Cancer

China
Ruijin Hospital

Recruiting

Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer

Stage IIIC Gastric Cancer

China
Fundacion Oncosur

Completed

Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer (neurabrax)

Breast Cancer

Spain
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NAPSPAC)

Advanced Pancreatic Cancer

China
Ying Lin

Recruiting

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation (IMPARP)

Her-2 Negative Breast Cancer | HRR Gene Mutation

China
Fudan University

Recruiting

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Breast Cancer

China
Jianjun Yang
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Di Wu

Recruiting

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

Melanoma

China
Shanghai Chest Hospital

Not yet recruiting

Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）

Esophageal Squamous Cell Carcinoma

China
Beijing Friendship Hospital

Unknown

Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Gastric Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Cervical Cancer | Fertility Preservation | Neoadjuvant Chemoimmunotherapy

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen...

Recruiting

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

Lung Cancer, Non-small Cell | Artificial Intelligence

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC (Compass-001)

Non-Small Cell Lung Cancer

China
Affiliated Hospital of Qinghai University

Unknown

Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

Gastric Cancer

China
Fudan University

Active, not recruiting

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Triple-Negative Breast Cancer

China
Chinese PLA General Hospital

Unknown

Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients

Cancer of Pancreas

China
Fudan University

Not yet recruiting

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

China
Fujian Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.; SunWay Biotech Co., LTD.

Not yet recruiting

Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Liver Metastases | Malignant Melanoma
National Health Research Institutes, Taiwan
National Taiwan University Hospital; National Cheng-Kung University Hospital

Completed

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers (SOLAR)

Gastric Cancer in Situ | Pancreatic Cancers | Biliary Cancers

Taiwan
Guangdong Association of Clinical Trials

Not yet recruiting

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Non-Small-Cell Lung Cancer
Shengjing Hospital

Recruiting

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

HER2-positive Gastric Cancer

China
AIPING ZHOU

Completed

Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Chinese PLA General Hospital

Unknown

Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Advanced Gastric Cancer

China
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
Fudan University

Unknown

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Fudan University

Recruiting

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Triple-Negative Breast Cancer

China
The First Affiliated Hospital of Xiamen University

Unknown

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Locally Advanced or Metastatic Gastric Adenocarcinoma

China
Fujian Medical University

Active, not recruiting

Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Advanced Gastric Cancer

China

3

Subscribe